John G. Compton - 19 Feb 2026 Form 4 Insider Report for 20/20 Biolabs, Inc.

Reporting relationship: Director
Issuer ticker: AIDX on Nasdaq
Reported as of: 19 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2026, 18:13:20 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ John G. Compton

Key filing fact

John G. Compton filed Form 4 for 20/20 Biolabs, Inc. on 23 Feb 2026.

Key facts

This page summarizes John G. Compton's Form 4 filing for 20/20 Biolabs, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 18:13.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002107487 Primary reporting owner

Compton John G.

Relationship: Director
Address: C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG
Signature: /s/ John G. Compton
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +7,669
Change %: +115%
Price: $0.000000
Shares after: 14,335
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Series A-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -7,669
Change %: -100%
Price
Shares after: 0
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,669
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.